Your session is about to expire
← Back to Search
Hormone Therapy
Abivertinib for Prostate Cancer
Phase 2
Waitlist Available
Research Sponsored by Sorrento Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through study completion at up to approximately 63 months
Awards & highlights
Study Summary
This trial is testing a new combination drug therapy for men with prostate cancer that has spread and is no longer responding to hormone therapy.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through study completion at up to approximately 63 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through study completion at up to approximately 63 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
6-month radiographic progression-free survival
Secondary outcome measures
6-month radiographic progression-free survival (rPFS)
Duration of response
Overall Response Rate
+5 moreSide effects data
From 2021 Phase 2 trial • 96 Patients • NCT0444000719%
Hyperglycaemia
13%
Leukocytosis
13%
Acute kidney injury
13%
Acute respiratory failure
10%
Thrombocytopenia
10%
Hepatic enzyme increased
8%
Alanine aminotransferase increased
8%
Urinary tract infection
8%
Pneumothorax
6%
Hypokalaemia
6%
Respiratory failure
6%
Pneumonia bacterial
6%
Hypotension
6%
Sepsis
6%
Constipation
4%
Hyponatraemia
4%
Anaemia
2%
Brain death
2%
Haematuria
2%
Ischaemic hepatitis
2%
Candida infection
2%
Septic shock
2%
Pneumonia
2%
Atrial fibrillation
2%
Multiple organ dysfunction syndrome
100%
80%
60%
40%
20%
0%
Study treatment Arm
Abivertinib With Standard of Care
Placebo With Standard of Care
Trial Design
2Treatment groups
Experimental Treatment
Group I: Abivertinib - Abiraterone-progressingExperimental Treatment2 Interventions
Abiraterone-progressing: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
Group II: Abivertinib - Abiraterone-naiveExperimental Treatment2 Interventions
Abiraterone-naive: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abivertinib
Not yet FDA approved
Abiraterone
FDA approved
Find a Location
Who is running the clinical trial?
Sorrento Therapeutics, Inc.Lead Sponsor
47 Previous Clinical Trials
1,864 Total Patients Enrolled
Mike Royal, MDStudy DirectorSorrento Therapeutics, Inc.
27 Previous Clinical Trials
1,395 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger